E-MTAB-1749 - ChIP-seq of human LNCaP prostate cancer cell line and MDA-MB-453 molecular apocrine breast cancer cell line with antibodies against androgen receptor (AR) with or without overexpression of FoxA1

Status
Released on 14 January 2014, last updated on 2 May 2014
Organism
Homo sapiens
Samples (2)
Protocols (10)
Description
We performed androgen receptor (AR) ChIP-seq after GFP control or FOXA1 over-expression in two AR driven cancer models; LNCaP prostate cancer cell line and MDA-MB-453 molecular apocrine breast cancer cell line.
Experiment types
ChIP-seq, ChiP-seq, compound treatment, replicate
Contact
Citation
Elevated FOXA1 enhances androgen receptor binding and function in aggressive prostate cancer. Robinson JLL; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Tilley WD; Neal DE; Carroll JS.
MINSEQE
Exp. designProtocolsFactorsProcessedSeq. reads
Files
Investigation descriptionE-MTAB-1749.idf.txt
Sample and data relationshipE-MTAB-1749.sdrf.txt
Processed data (1)E-MTAB-1749.processed.1.zip
Links